-
1
-
-
0037025173
-
Cancer. Addiction to oncogenes - the Achilles heal of cancer
-
Weinstein I.B. Cancer. Addiction to oncogenes - the Achilles heal of cancer. Science 2002, 297:63-64.
-
(2002)
Science
, vol.297
, pp. 63-64
-
-
Weinstein, I.B.1
-
2
-
-
84862999938
-
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
-
Misale S., et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012, 486:532-536.
-
(2012)
Nature
, vol.486
, pp. 532-536
-
-
Misale, S.1
-
3
-
-
84863000299
-
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
-
Diaz L.A., et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012, 486:537-540.
-
(2012)
Nature
, vol.486
, pp. 537-540
-
-
Diaz, L.A.1
-
4
-
-
77950809059
-
A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations
-
Sharma S.V., et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010, 141:69-80.
-
(2010)
Cell
, vol.141
, pp. 69-80
-
-
Sharma, S.V.1
-
5
-
-
0035902180
-
Oncogenic kinase signalling
-
Blume-Jensen P., Hunter T. Oncogenic kinase signalling. Nature 2001, 411:355-365.
-
(2001)
Nature
, vol.411
, pp. 355-365
-
-
Blume-Jensen, P.1
Hunter, T.2
-
6
-
-
34248583886
-
MAP kinase signalling pathways in cancer
-
Dhillon A.S., et al. MAP kinase signalling pathways in cancer. Oncogene 2007, 26:3279-3290.
-
(2007)
Oncogene
, vol.26
, pp. 3279-3290
-
-
Dhillon, A.S.1
-
7
-
-
2342445635
-
The JAK/STAT signaling pathway
-
Rawlings J.S., et al. The JAK/STAT signaling pathway. J. Cell Sci. 2004, 117:1281-1283.
-
(2004)
J. Cell Sci.
, vol.117
, pp. 1281-1283
-
-
Rawlings, J.S.1
-
8
-
-
0034644539
-
Cell signaling by receptor tyrosine kinases
-
Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000, 103:211-225.
-
(2000)
Cell
, vol.103
, pp. 211-225
-
-
Schlessinger, J.1
-
9
-
-
10744233716
-
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
-
O'Brien S.G., et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 2003, 348:994-1004.
-
(2003)
N. Engl. J. Med.
, vol.348
, pp. 994-1004
-
-
O'Brien, S.G.1
-
10
-
-
33845444046
-
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
-
Druker B.J., et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 2006, 355:2408-2417.
-
(2006)
N. Engl. J. Med.
, vol.355
, pp. 2408-2417
-
-
Druker, B.J.1
-
11
-
-
84879071011
-
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer
-
Shaw A.T., et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N. Engl. J. Med. 2013, 368:2385-2394.
-
(2013)
N. Engl. J. Med.
, vol.368
, pp. 2385-2394
-
-
Shaw, A.T.1
-
12
-
-
77953930730
-
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR
-
Maemondo M., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 2010, 362:2380-2388.
-
(2010)
N. Engl. J. Med.
, vol.362
, pp. 2380-2388
-
-
Maemondo, M.1
-
13
-
-
84857502654
-
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
-
Rosell R., et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012, 13:239-246.
-
(2012)
Lancet Oncol.
, vol.13
, pp. 239-246
-
-
Rosell, R.1
-
14
-
-
84884736973
-
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations
-
Sequist L.V., et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J. Clin. Oncol. 2013, 31:3327-3334.
-
(2013)
J. Clin. Oncol.
, vol.31
, pp. 3327-3334
-
-
Sequist, L.V.1
-
15
-
-
84892997539
-
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
-
Wu Y.L., et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014, 15:213-222.
-
(2014)
Lancet Oncol.
, vol.15
, pp. 213-222
-
-
Wu, Y.L.1
-
16
-
-
0035869407
-
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
-
Slamon D.J., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 2001, 344:783-792.
-
(2001)
N. Engl. J. Med.
, vol.344
, pp. 783-792
-
-
Slamon, D.J.1
-
17
-
-
33845886440
-
Lapatinib plus capecitabine for HER2-positive advanced breast cancer
-
Geyer C.E., et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. 2006, 355:2733-2743.
-
(2006)
N. Engl. J. Med.
, vol.355
, pp. 2733-2743
-
-
Geyer, C.E.1
-
18
-
-
79959795786
-
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
-
Chapman P.B., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 2011, 364:2507-2516.
-
(2011)
N. Engl. J. Med.
, vol.364
, pp. 2507-2516
-
-
Chapman, P.B.1
-
19
-
-
84885229945
-
Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer
-
Herrera-Abreu M.T., et al. Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer. Cancer Discov. 2013, 3:1058-1071.
-
(2013)
Cancer Discov.
, vol.3
, pp. 1058-1071
-
-
Herrera-Abreu, M.T.1
-
20
-
-
84860540538
-
Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas
-
Migliardi G., et al. Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas. Clin. Cancer Res. 2012, 18:2515-2525.
-
(2012)
Clin. Cancer Res.
, vol.18
, pp. 2515-2525
-
-
Migliardi, G.1
-
21
-
-
84890520181
-
Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations
-
Ganesan P., et al. Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations. Mol. Cancer Ther. 2013, 12:2857-2863.
-
(2013)
Mol. Cancer Ther.
, vol.12
, pp. 2857-2863
-
-
Ganesan, P.1
-
22
-
-
78649723255
-
PLX4032 in metastatic colon cancer patients with mutant BRAF tumors
-
abstract
-
Kopetz S., et al. PLX4032 in metastatic colon cancer patients with mutant BRAF tumors. J. Clin. Oncol. 2010, 28(Supplement):3534. abstract.
-
(2010)
J. Clin. Oncol.
, vol.28
, pp. 3534
-
-
Kopetz, S.1
-
23
-
-
79958026380
-
The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation
-
Mendoza M.C., et al. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem. Sci. 2011, 36:320-328.
-
(2011)
Trends Biochem. Sci.
, vol.36
, pp. 320-328
-
-
Mendoza, M.C.1
-
24
-
-
84870825008
-
JAK2/STAT5 inhibition circumvents resistance to PI3K/mTOR blockade: a rationale for cotargeting these pathways in metastatic breast cancer
-
Britschgi A., et al. JAK2/STAT5 inhibition circumvents resistance to PI3K/mTOR blockade: a rationale for cotargeting these pathways in metastatic breast cancer. Cancer Cell 2012, 22:796-811.
-
(2012)
Cancer Cell
, vol.22
, pp. 796-811
-
-
Britschgi, A.1
-
25
-
-
84867405669
-
Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation
-
Kim S.M., et al. Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation. Mol. Cancer Ther. 2012, 11:2254-2264.
-
(2012)
Mol. Cancer Ther.
, vol.11
, pp. 2254-2264
-
-
Kim, S.M.1
-
26
-
-
77952800807
-
Receptor tyrosine kinase coactivation networks in cancer
-
Xu A.M., Huang P.H. Receptor tyrosine kinase coactivation networks in cancer. Cancer Res. 2010, 70:3857-3860.
-
(2010)
Cancer Res.
, vol.70
, pp. 3857-3860
-
-
Xu, A.M.1
Huang, P.H.2
-
27
-
-
79953207364
-
Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase
-
Garrett J.T., et al. Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:5021-5026.
-
(2011)
Proc. Natl. Acad. Sci. U.S.A.
, vol.108
, pp. 5021-5026
-
-
Garrett, J.T.1
-
28
-
-
84859409756
-
Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3
-
McDonagh C.F., et al. Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3. Mol. Cancer Ther. 2012, 11:582-593.
-
(2012)
Mol. Cancer Ther.
, vol.11
, pp. 582-593
-
-
McDonagh, C.F.1
-
29
-
-
84884162850
-
Computational modeling of ERBB2-amplified breast cancer identifies combined ErbB2/3 blockade as superior to the combination of MEK and AKT inhibitors
-
Kirouac D.C., et al. Computational modeling of ERBB2-amplified breast cancer identifies combined ErbB2/3 blockade as superior to the combination of MEK and AKT inhibitors. Sci. Signal. 2013, 6:ra68.
-
(2013)
Sci. Signal.
, vol.6
, pp. ra68
-
-
Kirouac, D.C.1
-
30
-
-
84877593565
-
De-repression of PDGFRbeta transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients
-
Akhavan D., et al. De-repression of PDGFRbeta transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients. Cancer Discov. 2013, 3:534-547.
-
(2013)
Cancer Discov.
, vol.3
, pp. 534-547
-
-
Akhavan, D.1
-
31
-
-
73649102105
-
Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC
-
Turke A.B., et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 2010, 17:77-88.
-
(2010)
Cancer Cell
, vol.17
, pp. 77-88
-
-
Turke, A.B.1
-
32
-
-
84878862323
-
Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer
-
Bardelli A., et al. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov. 2013, 3:658-673.
-
(2013)
Cancer Discov.
, vol.3
, pp. 658-673
-
-
Bardelli, A.1
-
33
-
-
80052793410
-
A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors
-
Sasaki T., et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res. 2011, 71:6051-6060.
-
(2011)
Cancer Res.
, vol.71
, pp. 6051-6060
-
-
Sasaki, T.1
-
34
-
-
84856999699
-
Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers
-
120ra117
-
Katayama R., et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci. Transl. Med. 2012, 4:120ra117.
-
(2012)
Sci. Transl. Med.
, vol.4
-
-
Katayama, R.1
-
35
-
-
77954586493
-
Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis
-
Benedettini E., et al. Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis. Am. J. Pathol. 2010, 177:415-423.
-
(2010)
Am. J. Pathol.
, vol.177
, pp. 415-423
-
-
Benedettini, E.1
-
36
-
-
40449113978
-
Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells
-
Shattuck D.L., et al. Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Cancer Res. 2008, 68:1471-1477.
-
(2008)
Cancer Res.
, vol.68
, pp. 1471-1477
-
-
Shattuck, D.L.1
-
37
-
-
84868273967
-
Strong EGFR signaling in cell line models of ERBB2-amplified breast cancer attenuates response towards ERBB2-targeting drugs
-
Henjes F., et al. Strong EGFR signaling in cell line models of ERBB2-amplified breast cancer attenuates response towards ERBB2-targeting drugs. Oncogenesis 2012, 1:e16.
-
(2012)
Oncogenesis
, vol.1
-
-
Henjes, F.1
-
38
-
-
67651174452
-
Pertuzumab increases epidermal growth factor receptor down-regulation by counteracting epidermal growth factor receptor-ErbB2 heterodimerization
-
Hughes J.B., et al. Pertuzumab increases epidermal growth factor receptor down-regulation by counteracting epidermal growth factor receptor-ErbB2 heterodimerization. Mol. Cancer Ther. 2009, 8:1885-1892.
-
(2009)
Mol. Cancer Ther.
, vol.8
, pp. 1885-1892
-
-
Hughes, J.B.1
-
39
-
-
84858268381
-
Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer
-
Gonzalez-Angulo A.M., et al. Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer. Clin. Proteomics 2011, 8:11.
-
(2011)
Clin. Proteomics
, vol.8
, pp. 11
-
-
Gonzalez-Angulo, A.M.1
-
40
-
-
84884167635
-
The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells
-
Meyer A.S., et al. The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells. Sci. Signal. 2013, 6:ra66.
-
(2013)
Sci. Signal.
, vol.6
, pp. ra66
-
-
Meyer, A.S.1
-
41
-
-
80051597880
-
Enhanced efficacy of IGF1R inhibition in pediatric glioblastoma by combinatorial targeting of PDGFRalpha/beta
-
Bielen A., et al. Enhanced efficacy of IGF1R inhibition in pediatric glioblastoma by combinatorial targeting of PDGFRalpha/beta. Mol. Cancer Ther. 2011, 10:1407-1418.
-
(2011)
Mol. Cancer Ther.
, vol.10
, pp. 1407-1418
-
-
Bielen, A.1
-
42
-
-
34248591612
-
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
-
Roberts P.J., Der C.J. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007, 26:3291-3310.
-
(2007)
Oncogene
, vol.26
, pp. 3291-3310
-
-
Roberts, P.J.1
Der, C.J.2
-
43
-
-
84893249799
-
PI3K and cancer: lessons, challenges and opportunities
-
Fruman D.A., Rommel C. PI3K and cancer: lessons, challenges and opportunities. Nat. Rev. Drug Discov. 2014, 13:140-156.
-
(2014)
Nat. Rev. Drug Discov.
, vol.13
, pp. 140-156
-
-
Fruman, D.A.1
Rommel, C.2
-
44
-
-
33947594129
-
Hyperactive Ras in developmental disorders and cancer
-
Schubbert S., et al. Hyperactive Ras in developmental disorders and cancer. Nat. Rev. Cancer 2007, 7:295-308.
-
(2007)
Nat. Rev. Cancer
, vol.7
, pp. 295-308
-
-
Schubbert, S.1
-
45
-
-
79960051265
-
Therapeutic strategies for targeting ras proteins
-
Gysin S., et al. Therapeutic strategies for targeting ras proteins. Genes Cancer 2011, 2:359-372.
-
(2011)
Genes Cancer
, vol.2
, pp. 359-372
-
-
Gysin, S.1
-
46
-
-
84888639050
-
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
-
Ostrem J.M., et al. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 2013, 503:548-551.
-
(2013)
Nature
, vol.503
, pp. 548-551
-
-
Ostrem, J.M.1
-
47
-
-
84878401236
-
Small molecule inhibition of the KRAS-PDEdelta interaction impairs oncogenic KRAS signalling
-
Zimmermann G., et al. Small molecule inhibition of the KRAS-PDEdelta interaction impairs oncogenic KRAS signalling. Nature 2013, 497:638-642.
-
(2013)
Nature
, vol.497
, pp. 638-642
-
-
Zimmermann, G.1
-
48
-
-
84859410770
-
Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements
-
Hayes D.N., et al. Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements. Clin. Cancer Res. 2012, 18:2056-2065.
-
(2012)
Clin. Cancer Res.
, vol.18
, pp. 2056-2065
-
-
Hayes, D.N.1
-
49
-
-
84863230465
-
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
-
Prahallad A., et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012, 483:100-103.
-
(2012)
Nature
, vol.483
, pp. 100-103
-
-
Prahallad, A.1
-
50
-
-
84861863158
-
EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib
-
Corcoran R.B., et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2012, 2:227-235.
-
(2012)
Cancer Discov.
, vol.2
, pp. 227-235
-
-
Corcoran, R.B.1
-
51
-
-
83455254767
-
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
-
Poulikakos P.I., et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 2011, 480:387-390.
-
(2011)
Nature
, vol.480
, pp. 387-390
-
-
Poulikakos, P.I.1
-
52
-
-
52149115126
-
ERK-dependent threonine phosphorylation of EGF receptor modulates receptor downregulation and signaling
-
Li X., et al. ERK-dependent threonine phosphorylation of EGF receptor modulates receptor downregulation and signaling. Cell. Signal. 2008, 20:2145-2155.
-
(2008)
Cell. Signal.
, vol.20
, pp. 2145-2155
-
-
Li, X.1
-
53
-
-
84863596086
-
MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors
-
Turke A.B., et al. MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors. Cancer Res. 2012, 72:3228-3237.
-
(2012)
Cancer Res.
, vol.72
, pp. 3228-3237
-
-
Turke, A.B.1
-
54
-
-
80555157475
-
Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers
-
Ebi H., et al. Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. J. Clin. Invest. 2011, 121:4311-4321.
-
(2011)
J. Clin. Invest.
, vol.121
, pp. 4311-4321
-
-
Ebi, H.1
-
55
-
-
84877630250
-
Coordinate direct input of both KRAS and IGF1 receptor to activation of PI3 kinase in KRAS-mutant lung cancer
-
Molina-Arcas M., et al. Coordinate direct input of both KRAS and IGF1 receptor to activation of PI3 kinase in KRAS-mutant lung cancer. Cancer Discov. 2013, 3:548-563.
-
(2013)
Cancer Discov.
, vol.3
, pp. 548-563
-
-
Molina-Arcas, M.1
-
56
-
-
84888125634
-
Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models
-
Flanigan S.A., et al. Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models. Clin. Cancer Res. 2013, 19:6219-6229.
-
(2013)
Clin. Cancer Res.
, vol.19
, pp. 6219-6229
-
-
Flanigan, S.A.1
-
57
-
-
77949732073
-
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
-
Poulikakos P.I., et al. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010, 464:427-430.
-
(2010)
Nature
, vol.464
, pp. 427-430
-
-
Poulikakos, P.I.1
-
58
-
-
77949685981
-
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
-
Hatzivassiliou G., et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010, 464:431-435.
-
(2010)
Nature
, vol.464
, pp. 431-435
-
-
Hatzivassiliou, G.1
-
59
-
-
74849109743
-
Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF
-
Heidorn S.J., et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010, 140:209-221.
-
(2010)
Cell
, vol.140
, pp. 209-221
-
-
Heidorn, S.J.1
-
60
-
-
84877825519
-
RAF inhibitors activate the MAPK pathway by relieving inhibitory autophosphorylation
-
Holderfield M., et al. RAF inhibitors activate the MAPK pathway by relieving inhibitory autophosphorylation. Cancer Cell 2013, 23:594-602.
-
(2013)
Cancer Cell
, vol.23
, pp. 594-602
-
-
Holderfield, M.1
-
61
-
-
84879795966
-
Paradoxical oncogenesis - the long-term effects of BRAF inhibition in melanoma
-
Gibney G.T., et al. Paradoxical oncogenesis - the long-term effects of BRAF inhibition in melanoma. Nat. Rev. Clin. Oncol. 2013, 10:390-399.
-
(2013)
Nat. Rev. Clin. Oncol.
, vol.10
, pp. 390-399
-
-
Gibney, G.T.1
-
62
-
-
84871037064
-
Progression of RAS-mutant leukemia during RAF inhibitor treatment
-
Callahan M.K., et al. Progression of RAS-mutant leukemia during RAF inhibitor treatment. N. Engl. J. Med. 2012, 367:2316-2321.
-
(2012)
N. Engl. J. Med.
, vol.367
, pp. 2316-2321
-
-
Callahan, M.K.1
-
63
-
-
84897142154
-
BRAF inhibitors induce metastasis in RAS mutant or inhibitor-resistant melanoma cells by reactivating MEK and ERK signaling
-
Sanchez-Laorden B., et al. BRAF inhibitors induce metastasis in RAS mutant or inhibitor-resistant melanoma cells by reactivating MEK and ERK signaling. Sci. Signal. 2014, 7:ra30.
-
(2014)
Sci. Signal.
, vol.7
, pp. ra30
-
-
Sanchez-Laorden, B.1
-
64
-
-
84898023140
-
Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3
-
Sun C., et al. Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3. Cell Rep. 2014, 7:86-93.
-
(2014)
Cell Rep.
, vol.7
, pp. 86-93
-
-
Sun, C.1
-
65
-
-
84900442808
-
Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tTumors
-
Lito P., et al. Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tTumors. Cancer Cell 2014, 25:697-710.
-
(2014)
Cancer Cell
, vol.25
, pp. 697-710
-
-
Lito, P.1
-
66
-
-
57349194139
-
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
-
Engelman J.A., et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat. Med. 2008, 14:1351-1356.
-
(2008)
Nat. Med.
, vol.14
, pp. 1351-1356
-
-
Engelman, J.A.1
-
67
-
-
84874613332
-
Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo
-
Posch C., et al. Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:4015-4020.
-
(2013)
Proc. Natl. Acad. Sci. U.S.A.
, vol.110
, pp. 4015-4020
-
-
Posch, C.1
-
68
-
-
84871183627
-
A first-in-human phase Ib study to evaluate the MEK inhibitor GDC-0973, combined with the pan-PI3K inhibitor GDC-0941, in patients with advanced solid tumors
-
LoRusso P., et al. A first-in-human phase Ib study to evaluate the MEK inhibitor GDC-0973, combined with the pan-PI3K inhibitor GDC-0941, in patients with advanced solid tumors. J. Clin. Oncol. 2012, 30(15_Suppl):2566.
-
(2012)
J. Clin. Oncol.
, vol.30
, Issue.15 SUPPL
, pp. 2566
-
-
LoRusso, P.1
-
69
-
-
84899048311
-
Pharmacodynamic biomarker-driven trial of MK-2206, and AKT inhibitor, with AZD6244 (selumetinib), a MEK inhibitor, in patients with advanced colorectal carcinoma
-
Speranza G., et al. Pharmacodynamic biomarker-driven trial of MK-2206, and AKT inhibitor, with AZD6244 (selumetinib), a MEK inhibitor, in patients with advanced colorectal carcinoma. J. Clin. Oncol. 2012, 30(15_Suppl):3529.
-
(2012)
J. Clin. Oncol.
, vol.30
, Issue.15 SUPPL
, pp. 3529
-
-
Speranza, G.1
-
70
-
-
84859765844
-
Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer
-
Duncan J.S., et al. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell 2012, 149:307-321.
-
(2012)
Cell
, vol.149
, pp. 307-321
-
-
Duncan, J.S.1
-
71
-
-
84869067183
-
Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas
-
Lito P., et al. Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell 2012, 22:668-682.
-
(2012)
Cancer Cell
, vol.22
, pp. 668-682
-
-
Lito, P.1
-
72
-
-
84861381332
-
Adaptive upregulation of FOXD3 and resistance to PLX4032/4720-induced cell death in mutant B-RAF melanoma cells
-
Basile K.J., et al. Adaptive upregulation of FOXD3 and resistance to PLX4032/4720-induced cell death in mutant B-RAF melanoma cells. Oncogene 2012, 31:2471-2479.
-
(2012)
Oncogene
, vol.31
, pp. 2471-2479
-
-
Basile, K.J.1
-
73
-
-
84864285794
-
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
-
Straussman R., et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012, 487:500-504.
-
(2012)
Nature
, vol.487
, pp. 500-504
-
-
Straussman, R.1
-
74
-
-
84864286442
-
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
-
Wilson T.R., et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012, 487:505-509.
-
(2012)
Nature
, vol.487
, pp. 505-509
-
-
Wilson, T.R.1
-
75
-
-
84897531613
-
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
-
Sun C., et al. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature 2014, 508:118-122.
-
(2014)
Nature
, vol.508
, pp. 118-122
-
-
Sun, C.1
-
76
-
-
84869499716
-
Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor
-
Seghers A.C., et al. Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor. Melanoma Res. 2012, 22:466-472.
-
(2012)
Melanoma Res.
, vol.22
, pp. 466-472
-
-
Seghers, A.C.1
-
77
-
-
84873728334
-
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
-
Das Thakur M., et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 2013, 494:251-255.
-
(2013)
Nature
, vol.494
, pp. 251-255
-
-
Das Thakur, M.1
-
78
-
-
0942287932
-
Effect of re-treatment with gefitinib ('Iressa' ZD1839) after acquisition of resistance
-
Kurata T., et al. Effect of re-treatment with gefitinib ('Iressa' ZD1839) after acquisition of resistance. Ann. Oncol. 2004, 15:173-174.
-
(2004)
Ann. Oncol.
, vol.15
, pp. 173-174
-
-
Kurata, T.1
-
79
-
-
20444456682
-
Retreatment of lung adenocarcinoma patients with gefitinib who had experienced favorable results from their initial treatment with this selective epidermal growth factor receptor inhibitor: a report of three cases
-
Yano S., et al. Retreatment of lung adenocarcinoma patients with gefitinib who had experienced favorable results from their initial treatment with this selective epidermal growth factor receptor inhibitor: a report of three cases. Oncol. Res. 2005, 15:107-111.
-
(2005)
Oncol. Res.
, vol.15
, pp. 107-111
-
-
Yano, S.1
-
80
-
-
80155142474
-
Rapamycin passes the torch: a new generation of mTOR inhibitors
-
Benjamin D., et al. Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat. Rev. Drug Discov. 2011, 10:868-880.
-
(2011)
Nat. Rev. Drug Discov.
, vol.10
, pp. 868-880
-
-
Benjamin, D.1
-
81
-
-
0035970744
-
The BPS domain of Grb10 inhibits the catalytic activity of the insulin and IGF1 receptors
-
Stein E.G., et al. The BPS domain of Grb10 inhibits the catalytic activity of the insulin and IGF1 receptors. FEBS Lett. 2001, 493:106-111.
-
(2001)
FEBS Lett.
, vol.493
, pp. 106-111
-
-
Stein, E.G.1
-
82
-
-
79958696336
-
Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling
-
Yu Y., et al. Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science 2011, 332:1322-1326.
-
(2011)
Science
, vol.332
, pp. 1322-1326
-
-
Yu, Y.1
-
83
-
-
79958696694
-
The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling
-
Hsu P.P., et al. The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 2011, 332:1317-1322.
-
(2011)
Science
, vol.332
, pp. 1317-1322
-
-
Hsu, P.P.1
-
84
-
-
32944457518
-
MTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
-
O'Reilly K.E., et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006, 66:1500-1508.
-
(2006)
Cancer Res.
, vol.66
, pp. 1500-1508
-
-
O'Reilly, K.E.1
-
85
-
-
80655126355
-
MTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling
-
Rodrik-Outmezguine V.S., et al. mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. Cancer Discov. 2011, 1:248-259.
-
(2011)
Cancer Discov.
, vol.1
, pp. 248-259
-
-
Rodrik-Outmezguine, V.S.1
-
86
-
-
78651458656
-
AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity
-
Chandarlapaty S., et al. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 2011, 19:58-71.
-
(2011)
Cancer Cell
, vol.19
, pp. 58-71
-
-
Chandarlapaty, S.1
-
87
-
-
79957917078
-
PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer
-
Serra V., et al. PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene 2011, 30:2547-2557.
-
(2011)
Oncogene
, vol.30
, pp. 2547-2557
-
-
Serra, V.1
-
88
-
-
84856989746
-
Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells
-
Muranen T., et al. Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. Cancer Cell 2012, 21:227-239.
-
(2012)
Cancer Cell
, vol.21
, pp. 227-239
-
-
Muranen, T.1
-
89
-
-
84897033468
-
Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors
-
Ducker G.S., et al. Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors. Oncogene 2014, 33:1590-1600.
-
(2014)
Oncogene
, vol.33
, pp. 1590-1600
-
-
Ducker, G.S.1
-
90
-
-
51349164790
-
Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer
-
Carracedo A., et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J. Clin. Invest. 2008, 118:3065-3074.
-
(2008)
J. Clin. Invest.
, vol.118
, pp. 3065-3074
-
-
Carracedo, A.1
-
91
-
-
84894557306
-
Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling
-
Will M., et al. Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling. Cancer Discov. 2014, 4:334-347.
-
(2014)
Cancer Discov.
, vol.4
, pp. 334-347
-
-
Will, M.1
-
92
-
-
84869194238
-
Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells
-
Grabinski N., et al. Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells. Mol. Cancer 2012, 11:85.
-
(2012)
Mol. Cancer
, vol.11
, pp. 85
-
-
Grabinski, N.1
-
93
-
-
84906238910
-
Combined therapy with RAD001 e BEZ235 overcomes resistance of PET immortalized cell lines to mTOR inhibition
-
Passacantilli I., et al. Combined therapy with RAD001 e BEZ235 overcomes resistance of PET immortalized cell lines to mTOR inhibition. Oncotarget 2014, 5:5381-5391.
-
(2014)
Oncotarget
, vol.5
, pp. 5381-5391
-
-
Passacantilli, I.1
-
94
-
-
84868628069
-
Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response
-
McCubrey J.A., et al. Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. Oncotarget 2012, 3:954-987.
-
(2012)
Oncotarget
, vol.3
, pp. 954-987
-
-
McCubrey, J.A.1
-
95
-
-
84872387485
-
Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models
-
Corcoran R.B., et al. Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Cancer Cell 2013, 23:121-128.
-
(2013)
Cancer Cell
, vol.23
, pp. 121-128
-
-
Corcoran, R.B.1
-
96
-
-
78649729548
-
Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo
-
Meng J., et al. Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo. PLoS ONE 2010, 5:e14124.
-
(2010)
PLoS ONE
, vol.5
-
-
Meng, J.1
-
97
-
-
84922485593
-
RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells
-
Simona L., et al. RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells. Cell Rep. 2014, 10.1016/j.celrep.2014.07.033.
-
(2014)
Cell Rep.
-
-
Simona, L.1
-
98
-
-
84905007559
-
Combined inhibition of BRAF and MEK in melanoma patients
-
Infante J.R., Swanton C. Combined inhibition of BRAF and MEK in melanoma patients. Lancet Oncol. 2014, 15:908-910.
-
(2014)
Lancet Oncol.
, vol.15
, pp. 908-910
-
-
Infante, J.R.1
Swanton, C.2
-
99
-
-
55949096610
-
Kinase requirements in human cells: IV. Differential kinase requirements in cervical and renal human tumor cell lines
-
Grueneberg D.A., et al. Kinase requirements in human cells: IV. Differential kinase requirements in cervical and renal human tumor cell lines. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:16490-16495.
-
(2008)
Proc. Natl. Acad. Sci. U.S.A.
, vol.105
, pp. 16490-16495
-
-
Grueneberg, D.A.1
-
100
-
-
55949117661
-
Kinase requirements in human cells: I. Comparing kinase requirements across various cell types
-
Grueneberg D.A., et al. Kinase requirements in human cells: I. Comparing kinase requirements across various cell types. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:16472-16477.
-
(2008)
Proc. Natl. Acad. Sci. U.S.A.
, vol.105
, pp. 16472-16477
-
-
Grueneberg, D.A.1
-
101
-
-
84919393400
-
Phase I study of the selective BRAFV600 inhibitor encorafenib (LGX818) combined with cetuximab and with or without the α-specific PI3K inhibitor BYL719 in patients with advanced BRAF-mutant colorectal cancer
-
abstr
-
Van Geel R., et al. Phase I study of the selective BRAFV600 inhibitor encorafenib (LGX818) combined with cetuximab and with or without the α-specific PI3K inhibitor BYL719 in patients with advanced BRAF-mutant colorectal cancer. J. Clin. Oncol. 2014, 32(5s, suppl):3514. abstr.
-
(2014)
J. Clin. Oncol.
, vol.32
, Issue.5
, pp. 3514
-
-
Van Geel, R.1
|